Evidence map›Paper›PMID 34444325›Full record

ArticleInternational journal of environmental research and public health2021

Factors Affecting Rapid Cognitive Decline in Patients with Alzheimer's Disease: A Longitudinal Follow-Up Study.

Chih-Chuan Pan, Che-Sheng Chu, Chien-Liang Chen, Yao-Chung Chuang, Nai-Ching Chen

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
  6. Frontiers in aging neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chih-Chuan PanDepartment of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
Che-Sheng ChuDepartment of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.ORCID 0000-0002-6911-1839
Chien-Liang ChenDivision of Nephrology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.ORCID 0000-0002-9508-8396
Yao-Chung ChuangDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.ORCID 0000-0001-9131-7385
Nai-Ching ChenDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.ORCID 0000-0003-2684-0377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the preventive and risk factors of rapid cognitive decline in patients with Alzheimer's disease (AD). Using the Chang Gung Research Database (CGRD), we enrolled patients with AD aged over 65 years between 1 January 2001 and 30 May 2019, and followed up for at least two years. Rapid cognitive decline was defined by a Mini-Mental State Examination (MMSE) score decline of ≥4 in 2 years. A longer prescription of acetylcholinesterase inhibitors (AChEIs) was defined as 22 months based on the median treatment duration of the cohorts. The Cox proportional hazards regression model adjusted for age, sex, medication, and physical comorbidities was used to examine the candidate risk and protective factors. We analyzed data from 3846 patients with AD (1503 men, 2343 women) with a mean age and percentage of females of 77.8 ± 6.2 years and 60.9%, respectively. The mean duration of patients with AD receiving AChEIs was 658.7 ± 21.9 days. In general, 310 patients with AD showed a rapid cognitive decline, accounting for 8.1%. Treatment of a consecutive AChEI prescription for >22 months in patients with AD was a protective factor against rapid cognitive decline (adjusted hazard ratio (aHR) = 0.41, 95% confidence interval (CI) = 0.33-0.52,

Indexed as

Alzheimer DiseaseCognitive DysfunctionCholinesterase InhibitorsDisease ProgressionFemaleFollow-Up StudiesHumansMaleMental Status and Dementia TestsCholinesterase Inhibitorsacetylcholinesterase inhibitorsAlzheimer’s diseasemoderatorspredictorrapid cognitive decline

Identifiers

PMID34444325
PMCPMC8391399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.